About
Technology
Issues
FAQ
Links
Official Page
Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.